GET DAILY SIGNALSTenon Medical (TNON) Reports +22% Revenue Growth in Q3 2026
Key Takeaways
- Third quarter 2026 revenue reached $1.4 million, up 22% year-over-year and 12% sequentially from the second quarter.
- Gross profit rose 23% to $1.0 million, with gross margin holding at a strong 66.3%.
- Loss from operations narrowed to $3.1 million, improving from $3.4 million in the prior-year quarter.
- Net loss widened to $6.6 million, or $5.39 per share, driven by non-cash warrant and debt-related expenses.
- Revenue and earnings per share (EPS) both came in below analyst consensus estimates for the quarter.
- Tenon ended the quarter with $8.3 million in cash and no outstanding debt after repaying its convertible notes.
Why This Report Matters
Tenon Medical focuses on sacro-pelvic disorders through its Catamaran SI joint fusion system and the Symmetry platform gained via the SiVantage acquisition. For a small, pre-profitability medtech company like TNON, every earnings release carries extra significance. Investors track whether commercial adoption and margin discipline can keep pace with operating costs. The company has shown solid top-line expansion lately, yet sustained losses and financing needs remain key themes. This quarter tests whether revenue momentum, stable margins, and balance-sheet moves point toward lower cash burn over time.
The Quarter in Detail
For the period ended September 30, 2026, TNON posted revenue of $1.4 million, a 22% rise from $1.2 million a year earlier and a 12% sequential increase. Gross profit reached $1.0 million, up 23% year-over-year, while gross margin improved slightly to 66.3% from 65.9%. Operating loss narrowed to $3.1 million from $3.4 million. Net loss, however, expanded to $6.6 million, or $5.39 per share, versus $3.3 million, or $14.17 per share, in the prior-year quarter. The wider net loss stemmed mainly from non-cash items, including about $3.1 million in warrant inducement expense and roughly $0.7 million in non-cash interest on convertible notes repaid during the period. Both revenue and EPS missed analyst expectations.
Cash and equivalents stood at $8.3 million at quarter-end, up from $3.8 million at the close of 2025. The company raised about $15.6 million in gross proceeds and finished the quarter debt-free.
How the Market Responded
Sentiment toward TNON had already been weak ahead of the release, with the stock down sharply over the past three and twelve months. The results did not shift that view much in the short term, as revenue came in modestly below consensus and the headline loss per share looked wider than expected. Shares moved lower in after-hours trading. The market seems to weigh steady underlying growth and margin stability against ongoing cash burn and dilution from financing activity. The non-cash drivers behind the larger net loss may ease some worries, yet focus stays on whether core operating losses continue to shrink.
Key Items to Follow Next
Several factors will influence how the story develops. Revenue sustainability stands out first, given management’s link to rising adoption of the Catamaran and Symmetry platforms. Procedure volumes and the pace of new physician and distributor additions deserve attention. Gross-margin trends matter as well, since higher revenue should help absorb fixed production costs and support further improvement. Cost control is another focus, as operating expenses remain high relative to the revenue base. The balance sheet looks stronger after the debt repayment and cash raise, but repeated financing raises dilution concerns for the future. Finally, execution on the SiVantage assets, including the Symmetry Plus platform, could provide additional growth momentum in coming quarters.
Exploring Market Ideas with AI Tools
When reviewing TNON alongside peers, I often turn to Tickeron’s AI Screener to apply consistent filters across technical patterns, fundamentals, and performance metrics. It helps surface comparable names and emerging signals without manual effort. In my experience, these tools add structure when scanning broader opportunities in the medtech space or other sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TNON in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
TNON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 31 cases where TNON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TNON's RSI Oscillator exited the oversold zone, 31 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNON advanced for three days, in 132 of 163 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNON as a result. In 72 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 50-day moving average for TNON moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TNON entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.227) is normal, around the industry mean (4.142). P/E Ratio (-0.038) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.218) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. TNON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement